Date | Shareholders' Equity | Minority Interest | Total Equity | Total Stockholders Equity and Liabilities |
---|
CEO | Mr. Indranil Dey |
IPO Date | Nov. 10, 2021 |
Location | United States |
Headquarters | 360 Massachusetts Avenue |
Employees | 10 |
Sector | Health Care |
Industries |
Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Past 5 years
USD 2.78
USD 1.05
USD 3.26
USD 1.61
StockViz Staff
January 15, 2025
Any question? Send us an email